Opendata, web and dolomites

PRISAR2 SIGNED

proactive monitoring of cancer as an alternative to surgery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PRISAR2" data sheet

The following table provides information about the project.

Coordinator
PERCUROS BV 

Organization address
address: PLESMANLAAN 1
city: LEIDEN
postcode: 2333 BZ
website: www.percuros.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 2˙484˙000 €
 EC max contribution 2˙484˙000 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2019
 Funding Scheme MSCA-RISE
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PERCUROS BV NL (LEIDEN) coordinator 331˙200.00
2    CHIPDX IVS DK (VAERLOSE) participant 165˙600.00
3    HEINRICH-HEINE-UNIVERSITAET DUESSELDORF DE (DUSSELDORF) participant 165˙600.00
4    TECHNICKA UNIVERZITA VO ZVOLENE SK (ZVOLEN) participant 165˙600.00
5    UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS DE (GOETTINGEN) participant 138˙000.00
6    ASSOCIAZIONE TOURISM IT (NEMI) participant 124˙200.00
7    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 110˙400.00
8    TACIT BIO INNOVATION LIMITED UK (SUTTON COLDFIELD) participant 110˙400.00
9    TECOBIOSCIENCES GMBH DE (LANDSHUT) participant 110˙400.00
10    UNIVERSITA DEGLI STUDI DI CAMERINO IT (CAMERINO) participant 110˙400.00
11    UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II IT (NAPOLI) participant 110˙400.00
12    DATAR CANCER GENETICS (EUROPE) GMBH DE (ECKERSDORF) participant 101˙200.00
13    PROGREDUM GMBH DE (KAISERSLAUTERN) participant 92˙000.00
14    DES SOLUTIO - SOLUCOES E CONSULTORIA CIENTIFICA LDA PT (CHARNECA DE CAPARICA) participant 82˙800.00
15    ASSOCIAZIONE HAND IN HAND IT (NEMI) participant 69˙000.00
16    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 55˙200.00
17    FUJIFILM SONOSITE BV NL (AMSTERDAM) participant 55˙200.00
18    NEMI TERRITORIO E TURISMO IT (NEMI) participant 55˙200.00
19    SERANOVO BV NL (LEIDEN) participant 55˙200.00
20    SURGIMAB SAS FR (MONTPELLIER) participant 55˙200.00
21    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 55˙200.00
22    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 55˙200.00
23    UNIVERSITE DE STRASBOURG FR (STRASBOURG) participant 55˙200.00
24    HAMMERSMITH MEDICINES RESEARCH LTD UK (LONDON) participant 27˙600.00
25    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 27˙600.00

Map

 Project objective

From 2016 -2019, the “first” PRISAR consortium implemented the first Dutch RISE project of H2020 to investigate the use of imaging technologies and hybrid fluorescence/radionuclide probes for the surgical intervention of cancer. This PRISAR project provided a career-enabling human resource plethora of inter-disciplinary and inter-sectoral secondments, which resulted in the development, of not only a hybrid probe for image-guided surgery, but also a variety of tools and instruments. We now propose a new project, PRISAR2, to implement the next logical phase of this work, which is to clinically translate new and innovative monitoring technologies from industry. This will provide better patient selection and increase the surveillance window to allow for better treatment options over time and avoid surgery. This will involve developing new ‘watch and wait’ strategies to study the behaviour of the cancer so that any risks can be minimized. This would lead to a better clinical outcome and quality of life (QOL) for the patient and maximize the benefits of an active monitoring policy for both the patient and the healthcare system. When a patient is discovered to have cancer, one of the primary goals is to have the tumour removed by surgery. Here, however, we aim to (a) develop new monitoring technologies from industry so that the surveillance window can be increased to allow for better treatment options over time and to avoid surgery, (b) develop new ‘watch and wait’ strategies in order to study the behaviour of the cancer so that any risks to the patient can be minimised leading to a better clinical outcome and (c) train a new generation of preclinical and clinical scientists to be able to implement this new concept as standard of care and to maximise the benefits of an active monitoring policy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRISAR2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PRISAR2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

CONMECH (2019)

Nonsmooth Contact Dynamics

Read More  

ENDORSE (2018)

Safe, Efficient and Integrated Indoor Robotic Fleet for Logistic Applications in Healthcare and Commercial Spaces

Read More  

VIDEC (2020)

Visualizing Death Inducing Protein Complexes

Read More